Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-01-11T11:43:50.117Z Has data issue: false hasContentIssue false
  • English
  • Français

Empirical Investigation of Ethical Challenges Related to the Use of Biological Therapies

Published online by Cambridge University Press:  01 January 2021

Tara Bladt ,
Thomas Vorup-Jensen ,
Eva Sædder  and
Mette Ebbesen
Get access Rights & Permissions [Opens in a new window]

Abstract

The aim of this study was to investigate the ethical dilemma of prioritising financial resources to expensive biological therapies. For this purpose, the four principles of biomedical ethics formulated by ethicists Tom Beauchamp and James Childress were used as a theoretical framework. Based on arguments of justice, Beauchamp and Childress advocate for a health care system organised in line with the Danish system. Notably, our study was carried out in a Danish setting.

Type
Independent Articles
Information
Journal of Law, Medicine & Ethics , Volume 48 , Issue 3: A Bold Agenda for the Next Steps in Health Reform , Fall 2020 , pp. 567 - 578
Copyright
Copyright © American Society of Law, Medicine and Ethics 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ecker, D. M., Jones, S. D., and Levine, H. L., ‘The Therapeutic Monoclonal Antibody Market’, mAbs 7 no. 1 (2015): 9–14.CrossRefGoogle ScholarPubMed
Beauchamp, T. L. and Childress, J. F., Principles of Biomedical Ethics, 7th edition (New York: Oxford University Press, 2013): at 249–301 (Chapter: Justice).Google Scholar
The Danish Council on Ethics (Det Etiske Råd), Just Prioritisation in the Danish Health Care System (Retfærdig prioritering i det danske sundhedsvæsen), Copenhagen, 2018.Google Scholar
The Danish Council on Ethics (Det Etiske Råd), Just Prioritisation in the Danish Health Care System—Background (Retfærdig prioritering i det danske sundhedsvæsen - baggrundsnotat), Copenhagen, 2018.Google Scholar
Fossheim, H. and Ingierd, H., Research and Money (Forskning og penger, 2012), available at <http://etikkorn.no/aktuelt/publikasjoner/forskning-og-penger> (last visited September 8, 2020).+(last+visited+September+8,+2020).>Google Scholar
Bioethics Commission, Federal Chancellery, Medicine and Economics—Opinion of the Bioethics Commission, Vienna, 2018.Google Scholar
The German Ethics Council, Medical Benefits and Costs in Healthcare: The Normative Role of their Evaluation, Berlin, 2013.Google Scholar
Durvasula, R., Kelly, J., Schleyer, A., Anawalt, B. D., Somani, S., and Dellit, T. H., “Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System,” Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System, 11, no. 2 (2018): 65–73.Google Scholar
Maio, G., “Can Help for Patients be too Expensive? Ethical Considerations and End-Stage Lung Disease,” Can Help for Patients be too Expensive? Ethical Considerations and End-Stage Lung Disease, 82, no. 5 (2011): 395–399.Google Scholar
Id.Google Scholar
Nord, E., “The Desirability of a Condition Versus the Well Being and Worth of a Person,” The Desirability of a Condition Versus the Well Being and Worth of a Person, 10, no. 7 (2001): 579–581.Google Scholar
Beauchamp and Childress, supra note 2, at 202-248 (Chapter: Beneficence).Google Scholar
Beauchamp, T. L. and Childress, J. F., Principles of Biomedical Ethics, 7th edition (New York: Oxford University Press, 2013).Google Scholar
Beauchamp and Childress, supra note 13, at 1-25 (Chapter: Moral Norms).Google Scholar
Santoro, F. A., Rothe, M. J., and Strober, B. E., “Ethical Considerations when Prescribing Biologics in Dermatology,” Ethical Considerations when Prescribing Biologics in Dermatology, 30, no. 5 (2012): 492–495.Google Scholar
Id.Google Scholar
Fleck, L. M. and Danis, M., “How Should Therapeutic Decisions about Expensive Drugs Be Made in Imperfect Environments?” How Should Therapeutic Decisions about Expensive Drugs Be Made in Imperfect Environments? 19, no. 2 (2017): 147–156.Google ScholarPubMed
Id.Google Scholar
Beauchamp and Childress, supra note 13.Google Scholar
Ebbesen, M. and Pedersen, B. D., “Empirical Investigation of the Ethical Reasoning of Physicians and Molecular Biologists— the Importance of the Four Principles of Biomedical Ethics,” Empirical Investigation of the Ethical Reasoning of Physicians and Molecular Biologists— the Importance of the Four Principles of Biomedical Ethics, 2, no. 23 (2007): 1–16.Google Scholar
Id.Google Scholar
Houman, A. L., “3.3 million Danes have a Private Health Insurance” (3,3 mio. danskere har private sundhedsforsikringer) available at <https://finanswatch.dk/Finansnyt/Forsikring___Pension/article9375675.ece> (last visited Sept. 2, 2020).+(last+visited+Sept.+2,+2020).>Google Scholar
Ministry of Health (Sundheds- og Ældreministeret), “Note of Principles About Prioritising Hospital Medicine” (Princippapir om prioritering for sygehuslægemidler) available at <https://medicinraadet.dk/media/1oxfmhs7/ad-pkt-4-folketingets-7-principper-for-prioritering-af-sygehuslaegemidler_final-a.pdf> (last visited September 2, 2020).+(last+visited+September+2,+2020).>Google Scholar
Amgros, Amgros Hospital Medicine 2015 (Amgros Sygehusmedicin 2015), 2015.Google Scholar
The Danish Medicines Agency (Lægemiddelstyrelsen), Remsima, available at <https://medicinpriser.dk/Default.aspx?id=15&vnr=069790> (Last visited August 13, 2020); The price movement of Remsima pr unit can be seen here: <https://medicinpriser.dk/Default.aspx?id=15&vnr=069790> (choose “price development” (Prisudvikling) and insert date, e.g. november 2017); The Danish Medicines Agency (Lægemiddelstyrelsen), Lemtrada, available at <https://medicinpriser.dk/Default.aspx?id=15&vnr=165070> (Last visited Sept. 2, 2020). The price movement of Lemtrada pr unit since November 2017 can be seen here: <https://medicinpriser.dk/Default.aspx?id=15&vnr=165070> (choose “price development” (Prisudvikling) and insert date, e.g. november 2017).+(Last+visited+August+13,+2020);+The+price+movement+of+Remsima+pr+unit+can+be+seen+here:++(choose+“price+development”+(Prisudvikling)+and+insert+date,+e.g.+november+2017);+The+Danish+Medicines+Agency+(Lægemiddelstyrelsen),+Lemtrada,+available+at++(Last+visited+Sept.+2,+2020).+The+price+movement+of+Lemtrada+pr+unit+since+November+2017+can+be+seen+here:++(choose+“price+development”+(Prisudvikling)+and+insert+date,+e.g.+november+2017).>Google Scholar
Gamez-Belmonte, R., Hernandez-Chirlaque, C., Arredondo-Amador, M., Aranda, C. J., Gonzalez, R., Martinez-Augustin, O., and Sanchez de Medina, F., “Biosimilars: Concepts and Controversies,” Pharmacological Research 133 (2018): 251–264.CrossRefGoogle ScholarPubMed
Hey, A., “History and Practice: Antibodies in Infectious Diseases,” History and Practice: Antibodies in Infectious Diseases, 3, no. 2 (2015): 1–15.Google Scholar
Gamez-Belmonte, supra note 26.Google Scholar
Id.Google Scholar
Amgros, “New International Record in Biosimilar Switching (Ny international rekord i biosimilært skift), available at <https://www.amgros.dk/viden-og-analyser/artikler/ny-international-rekord-i-biosimilaert-skifte/> (Last visited Sept. 2, 2020).+(Last+visited+Sept.+2,+2020).>Google Scholar
Dendrou, C.A., Fugger, L., and Friese, M.A., “Immunopathology of Multiple Sclerosis,” Immunopathology of Multiple Sclerosis, 15, no. 9 (2015): 545–558.Google Scholar
Beauchamp and Childress, supra note 13.Google Scholar
Beauchamp and Childress, supra note 13, at 30-55 (chapter: Moral Character).Google Scholar
Beauchamp, T. L., “A Defense of the Common Morality,” A Defense of the Common Morality, 13, no. 3 (2003): 259–274.Google Scholar
Beauchamp, T. L., “Informed Consent: Its History, Meaning, and Present Challenges,” Informed Consent: Its History, Meaning, and Present Challenges, 20, no. 4 (2011): 515–523.Google Scholar
Beauchamp, supra note 34.Google Scholar
Halkoaho, A., Pietila, A. M., Ebbesen, M., Karki, S., and Kangasniemi, M., “Cultural Aspects Related to Informed Consent in Health Research: A Systematic Review,” Cultural Aspects Related to Informed Consent in Health Research: A Systematic Review, 23, no. 6 (2016): 698–712.Google Scholar
Beauchamp, supra note 35.Google Scholar
Beauchamp and Childress, supra note 13, at 101-149 (Chapter: Respect for Autonomy).Google Scholar
Id.Google Scholar
Id.Google Scholar
Beauchamp and Childress, supra note 13, Preface to the seventh edition.Google Scholar
Holm, S., “Not Just Autonomy—The Principles of American Biomedical Ethics,” Not Just Autonomy—The Principles of American Biomedical Ethics, 21, no. 6 (1995): 332–338.Google Scholar
Beauchamp, supra note 34.Google Scholar
Silverman, D., Doing Qualitative Research (London: Sage, 2013): at 141–158 (Chapter: How many cases do you need).Google Scholar
Lindseth, A. and Norberg, A., “A Phenomenological Hermeneutical Method for Researching Lived Experience,” A Phenomenological Hermeneutical Method for Researching Lived Experience, 18, no. 2 (2004): 145–153.Google Scholar
Ebbesen, M. and Pedersen, B. D., “Using Empirical Research to Formulate Normative Ethical Principles in Biomedicine,” Medicine, Health Care and Philosophy 10, no 1 (2007): 3–48.CrossRefGoogle ScholarPubMed
Beauchamp and Childress, supra note 2, at 101-149 (Chapter: Respect for Autonomy).Google Scholar
Beauchamp and Childress, supra note 13.Google Scholar